FloraWorks Announces Peer-Reviewed Publication of Groundbreaking Sleep Study on TruCBN(TM)
TruCBN(TM) is the first cannabinoid proven to be a safe and effective sleep aid in the largest blinded, randomized, placebo-controlled...
Clinical Trial
Sona Nanotech to Arrange Private Placement Financing
Halifax, Nova Scotia--(Newsfile Corp. - July 31, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is...
inPhronesis Announces Name Change to inThought Labs
The new name highlights the combined capabilities of decision support expertise and advanced technology solutions ORLANDO, Fla., July 30, 2024...
Clinical Trial Management System (CTMS) Market size is set to grow by USD 1.86 billion from 2024-2028, Increasing healthcare expenditure to boost the market growth, Technavio
NEW YORK, July 30, 2024 /PRNewswire/ -- The global clinical trial management system (CTMS) market size is estimated to grow by...
Agilisium Achieves AWS Life Sciences Competency Status
LOS ANGELES, July 30, 2024 /PRNewswire/ -- Agilisium, a pioneering leader in Data Analytics, Cloud, and Life Science solutions, today announced...
eClinical Solutions Market worth $22.1 billion by 2029 driven by Rising Chronic Illness Rates | MarketsandMarkets™
CHICAGO, July 30, 2024 /PRNewswire/ -- The global eClinical Solutions Market is expected to grow from USD 11.6 billion in 2024...
Slope Appoints Jim Munz as Chief Product & Technology Officer
Former Veeva and ERT clinical trial technology executive will drive strategy towards a complete, tech-enabled biospecimen lifecycle solution RICHMOND, Va.,...
Next Presentation in Record-Breaking Sleep Apnea Webinar Series Announced
Live presentations by leading sleep researchers available globally to front-line clinicians MURFREESBORO, Tenn., July 30, 2024 /PRNewswire/ -- SleepWorld Magazine...
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
— HBM Healthcare Investments, OrbiMed and Sphera Biotech Master Fund LP Participated in the Financing that Extends Cash Runway Potentially...
Georgiamune Announces First Patient Dosed in A First-In-Class Phase 1 Cancer Treatment Trial of GIM-531
GAITHERSBURG, Md., July 30, 2024 (GLOBE NEWSWIRE) -- Today, Georgiamune Inc., a privately held, clinical-stage biotechnology company, announced that the first...
Nascent Biotech Presents at the July Emerging Growth Conference
Nascent CEO-Sean Carrick-Discusses Phase I Results and Forward Clinical Strategy while laying out Investment Opportunity of the Company NORTH PALM...
PharmAla Provides Comprehensive Investor Update Following Release of Q3 Financial Statement
TORONTO, July 30, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology...
CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies
Strategic in-license from Cortice Bioscience is highly synergistic with the ongoing potentially pivotal Berubicin program and demonstrates further commitment to...
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
Preclinical data showed strong antibody responses with no measurable pro-inflammatory T cell responses against AßO and support novel approach for...
Cassava Sciences Announces Expansion of Open-Label Extension Trials
Ongoing open-label extension trials of simufilam in Alzheimer’s disease to be extended by up to an additional 36 months. The...
Yamo Pharmaceuticals Announces Positive Topline Results from Phase 2 Study of L1-79 for the Treatment of the Core Symptoms of Autism
Data shows L1-79 offers a statistically significant improvement compared to placebo in socialization, as well as the investigator- and parent-rated...
NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference
SNK01, a cryopreserved autologous non-genetically modified NK cell product, is able to effectively reduce α-synuclein (α-syn) protein levels in the...
Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease
The U.S. addressable market for Dry Eye Disease is valued at over $3 billion by independent sourcesNEW YORK, July 30,...
IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001
Phase 2 OVATION 2 Study of IMNN-001 administered with standard-of-care chemotherapy as first-line treatment demonstrates a hazard ratio of 0.74...
180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake
PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- 180 Life...